NCPC(SH:600812) Ge Long Hui A P P·2025-09-02 10:30Core Viewpoint - North China Pharmaceutical (600812.SH) has received the drug registration certificate for injectable vancomycin hydrochloride (0.5g) from the National Medical Products Administration, indicating the product meets the basic entry requirements for centralized procurement and has equivalent efficacy to the original product [1] Group 1: Product Information - Injectable vancomycin hydrochloride primarily acts by inhibiting bacterial cell wall biosynthesis and can alter bacterial cell membrane permeability and RNA synthesis [1] - The intravenous administration is suitable for infections caused by methicillin-resistant Staphylococcus aureus and other bacteria, including conditions such as sepsis, infective endocarditis, osteomyelitis, arthritis, burns, surgical wound infections, pneumonia, lung abscess, empyema, peritonitis, and meningitis [1] - The oral form is indicated for antibiotic-associated pseudomembranous colitis caused by Clostridium difficile and staphylococcal enterocolitis [1] Group 2: Market Position and Strategy - The approval of injectable vancomycin hydrochloride enhances the company's product portfolio in the anti-infection field, building on its existing product, Vanxun (injectable deacetyl vancomycin hydrochloride) [1] - This development is expected to effectively improve the company's competitive position in the market for anti-infection products [1]